T. Rowe Price Associates’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-2,780
| Closed | -$9K | – | 2906 |
|
|
2023
Q3 | $9K | Sell |
2,780
-1,700
| -38% | -$5.5K | ﹤0.01% | 2865 |
|
|
2023
Q2 | $139K | Sell |
4,480
-2,720
| -38% | -$84.4K | ﹤0.01% | 2621 |
|
|
2023
Q1 | $357K | Hold |
7,200
| – | – | ﹤0.01% | 2261 |
|
|
2022
Q4 | $177K | Hold |
7,200
| – | – | ﹤0.01% | 2570 |
|
|
2022
Q3 | $478K | Buy |
7,200
+1,000
| +16% | +$66.4K | ﹤0.01% | 2145 |
|
|
2022
Q2 | $257K | Hold |
6,200
| – | – | ﹤0.01% | 2499 |
|
|
2022
Q1 | $312K | Hold |
6,200
| – | – | ﹤0.01% | 2529 |
|
|
2021
Q4 | $372K | Hold |
6,200
| – | – | ﹤0.01% | 2515 |
|
|
2021
Q3 | $307K | Hold |
6,200
| – | – | ﹤0.01% | 2564 |
|
|
2021
Q2 | $353K | Sell |
6,200
-1,944
| -24% | -$111K | ﹤0.01% | 2524 |
|
|
2021
Q1 | $468K | Buy |
8,144
+6,690
| +460% | +$384K | ﹤0.01% | 2397 |
|
|
2020
Q4 | $99K | Buy |
1,454
+753
| +107% | +$51.3K | ﹤0.01% | 2624 |
|
|
2020
Q3 | $178K | Buy |
+701
| New | +$178K | ﹤0.01% | 2438 |
|